Dr Theresa Lavallee | Head of Translational Medicine
Parker Institute for Cancer Immunotherapy

Dr Theresa Lavallee, Head of Translational Medicine, Parker Institute for Cancer Immunotherapy

Theresa LaVallee has more than 25 years of research and industry experience with a broad knowledge in the discovery and development of drug candidates and portfolio management.  Theresa is Head of Translational Medicine at the Parker Institute for Cancer Immunotherapy and previously served as Senior Vice President, Regulatory and Precision Medicine at Celldex Therapeutics and prior to that was Senior Vice President Translational Medicine and Product Development at Kolltan Pharmaceuticals.  She also was Senior Director Translational Medicine at MedImmune and EntreMed.  In these roles, she has advanced drugs in oncology, immunology and inflammation from discovery through late state development.  Theresa has a depth of expertise in Translational Medicine to enable science driven development decisions and to implement effective use of biomarker assays in clinical studies.  She is author or co-author of more than 50 publications and abstracts with a focus on Translational Medicine approaches in clinical development.  She received her Ph.D. degree from University of California, Los Angeles and her B.A. degree from the University of California, Santa Barbara.  Theresa completed her postdoctoral research at the American Red Cross Holland Laboratory. 

Appearances:



West Coast Day 3 @ 12:10

Panel: Integrating our understanding of the tumor microenvironment and the microbiome to inform the development of I-O treatment

  • Our current understanding the biology of the tumor microenvironment and microbiome in cancer.
  • How can we apply this to the development of novel immunotherapies?
  • Examples of data sharing efforts and industry/ academic collaborations

West Coast Day 3 @ 2:20

Accelerating progress of precision immunotherapy from laboratory to clinic through strategic collaborations

  • Progress through research, clinical trials and genomic analysis
  • Will these projects lead to us grouping cancers differently, e.g. according to genetic faults?
  • How are we working together to integrate this work and ensure we make therapies available to patients rapidly?
last published: 16/Oct/18 14:45 GMT

back to speakers

Sign Up for Event Updates

Contact us

To sponsor or exhibit contact:
Oliver Breed
+44 (0)207 092 1156

oliver.breed@terrapinn.com


To speak:
Lauren Sheppard
+44 (0)207 092 1211

lauren.sheppard@terrapinn.com